152 related articles for article (PubMed ID: 20652353)
21. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
22. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
Zebenholzer K; Gall W; Wöber C
J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms of the Proinflammatory Cytokine Genes Modulate the Response to NSAIDs but Not to Triptans in Migraine Attacks.
Rubino E; Marcinnò A; Grassini A; Piella EM; Ferrandes F; Roveta F; Boschi S; Cermelli A; Gallone S; Savi L; Rainero I
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614097
[TBL] [Abstract][Full Text] [Related]
24. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
25. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.
Cameron C; Kelly S; Hsieh SC; Murphy M; Chen L; Kotb A; Peterson J; Coyle D; Skidmore B; Gomes T; Clifford T; Wells G
Headache; 2015; 55 Suppl 4():221-35. PubMed ID: 26178694
[TBL] [Abstract][Full Text] [Related]
26. Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients.
Eren OE; Gaul C; Peikert A; Gendolla A; Ruscheweyh R; Straube A
Sci Rep; 2020 Jul; 10(1):11382. PubMed ID: 32647152
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between GRIA1 polymorphisms and haplotypes with migraine without aura or response to triptans.
Cargnin S; Viana M; Mittino D; Bellomo G; Tassorelli C; Nappi G; Canonico PL; Terrazzino S
Neurol Sci; 2014 Mar; 35(3):421-7. PubMed ID: 24030684
[TBL] [Abstract][Full Text] [Related]
28. Family- and population-based association studies of monoamine oxidase A and autism spectrum disorders in Korean.
Yoo HJ; Lee SK; Park M; Cho IH; Hyun SH; Lee JC; Yang SY; Kim SA
Neurosci Res; 2009 Mar; 63(3):172-6. PubMed ID: 19100789
[TBL] [Abstract][Full Text] [Related]
29. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
[TBL] [Abstract][Full Text] [Related]
30. Pathways to the best fit of triptans for migraine patients.
Buzzi MG
Cephalalgia; 2008 Sep; 28 Suppl 2():21-7. PubMed ID: 18715329
[TBL] [Abstract][Full Text] [Related]
31. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
32. 5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms.
Velati D; Viana M; Cresta S; Mantegazza P; Testa L; Bettucci D; Rinaldi M; Sances G; Tassorelli C; Nappi G; Canonico PL; Martignoni E; Genazzani AA
Eur J Pharmacol; 2008 Feb; 580(1-2):43-7. PubMed ID: 18035351
[TBL] [Abstract][Full Text] [Related]
33. VNTR polymorphism in the monoamine oxidase A promoter region and cerebrospinal fluid catecholamine concentrations in forensic autopsy cases.
Matsusue A; Kubo SI; Ikeda T; Tani N; Maeda T; Kashiwagi M; Hara K; Waters B; Takayama M; Ikematsu N; Ishikawa T
Neurosci Lett; 2019 May; 701():71-76. PubMed ID: 30794821
[TBL] [Abstract][Full Text] [Related]
34. Bi-allelic and tri-allelic 5-HTTLPR polymorphisms and triptan non-response in cluster headache.
Schürks M; Frahnow A; Diener HC; Kurth T; Rosskopf D; Grabe HJ
J Headache Pain; 2014 Jul; 15(1):46. PubMed ID: 25043824
[TBL] [Abstract][Full Text] [Related]
35. Possible interaction between MAOA and DRD2 genes associated with antisocial alcoholism among Han Chinese men in Taiwan.
Wang TJ; Huang SY; Lin WW; Lo HY; Wu PL; Wang YS; Wu YS; Ko HC; Shih JC; Lu RB
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):108-14. PubMed ID: 17007976
[TBL] [Abstract][Full Text] [Related]
36. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
37. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
38. Evidences of Reduced Antioxidant Activity in Patients With Chronic Migraine and Medication-Overuse Headache.
Lucchesi C; Baldacci F; Cafalli M; Chico L; Lo Gerfo A; Bonuccelli U; Siciliano G; Gori S
Headache; 2015; 55(7):984-91. PubMed ID: 26129705
[TBL] [Abstract][Full Text] [Related]
39. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
[TBL] [Abstract][Full Text] [Related]
40. MAOA-uVNTR polymorphism in a Brazilian sample: further support for the association with impulsive behaviors and alcohol dependence.
Contini V; Marques FZ; Garcia CE; Hutz MH; Bau CH
Am J Med Genet B Neuropsychiatr Genet; 2006 Apr; 141B(3):305-8. PubMed ID: 16526025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
